|
Interagency Coordinating Committee for Newborn Screening
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA, HRSA
|
NICHD
|
This committee makes recommendations for screening certain disorders, developing a system to adjudicate newborn screening expansion, and assist states in implementing programs to test for the recommended conditions.
|
|
Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, HRSA, IHS, SAMHSA
|
NIAAA, NICHD, NIDA
|
The Interagency Coordinating Committee on Fetal Alcohol Syndrome (ICCFASD) was created in October 1996 in response to recommendations of an expert committee of the Institute of Medicine that NIAAA chair an effort to coordinate Federal activities on Fetal Alcohol Syndrome (FAS) and other disorders associated with prenatal alcohol exposure. ICCFASD works to improve communication, cooperation, and collaboration among disciplines and federal agencies that address issues of health, education, developmental disability, research, justice, and social services relevant to FAS and related disorders caused by prenatal alcohol exposure. The ICCFASD meets twice a year and frequently arranges special conferences.
|
|
Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIDDK, NICHD, NINDS
|
The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, HHS to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from NIH, FDA, and CDC, and is chaired by the NIDDK Director.
|
|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM)
|
Research Initiative
|
ATSDR, CDC, FDA
|
NIEHS, NCI, NEI, NIAID, NLM
|
The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) is an interagency committee of 15 Federal agencies that carries out specific duties prescribed by the ICCVAM Authorization Act, P.L. 106-545. The ICCVAM is administered by the National Toxicology Program''s Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), a component of the NIEHS.
NICEATM, in collaboration with ICCVAM and its international collaborators in Japan, the EU, and Canada, conducts research studies to evaluate the scientific validity of proposed new safety testing methods. NICEATM and ICCVAM also conduct international scientific peer review evaluations of proposed safety methods, and forward recommendations on scientifically valid methods to Federal agencies, which must adopt the proposed methods or provide a basis for not adopting them. NICEATM and ICCVAM also organize scientific workshops to evaluate the current state of the science on a wide range of toxicological and other safety endpoints.
|
|
Interagency Dual Use Outreach Working Group (IDOWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
This working group develops strategies to educate the research community about Dual Use Research of Concern (DURC) and the DURC-related USG policies.
|
|
Interagency Epilepsy Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA, HRSA, OS
|
NICHD, NIA, NIMH, NINDS
|
This working group identifies potential joint initiatives related to epilepsy and helps to coordinate epilepsy-related efforts and information exchange within the NIH and across the HHS.
|
|
Interagency Group on Alzheimer''s Disease and Related Dementias for implementation of the National Alzheimer''s Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA
|
NIA
|
This interagency group was established by HHS in response to the Congressional directive to address Alzheimer disease. Under the National Alzheimer’s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran’s Administration, National Science Foundation, and Department of Defense are also involved in this effort.
|
|
Interagency Midazolam Product Coordination Team
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
NINDS
|
A collaboration led by the Department of Health and Human Services (HHS) to facilitate activities, both research and regulatory, related to the Food and Drug Administration (FDA) approval of midazolam for use in treating nerve agent exposure.
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NIBIB, CSR, NCCIH, NCI, NCMHD, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR
|
The Inter-agency Modeling and Analysis Group (IMAG) is comprised of program directors from over 10 government agencies in the US including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably the multi-scale modeling (MSM) initiative, which was originally a multi-agency funding opportunity announcement and supplemented by various IMAG agencies through other funding opportunity announcements. The most recent multi-agency funding opportunity was issued in 2015 and expires in 2018. IMAG held its tenth-anniversary consortium meeting in March 2017.
|